• Po-Huang Chen, Yi-Ying Wu, Cho-Hao Lee, Chi-Hsiang Chung, Yu-Guang Chen, Tzu-Chuan Huang, Ren-Hua Yeh, Ping-Ying Chang, Ming-Shen Dai, Shiue-Wei Lai, Ching-Liang Ho, Jia-Hong Chen, Yeu-Chin Chen, Je-Ming Hu, Sung-Sen Yang, and Wu-Chien Chien.
• Department of General Medicine.
• Medicine (Baltimore). 2021 May 7; 100 (18): e25756e25756.

AbstractWe conducted a population-based cohort study enrolling patients with Stage II and III colon cancer receiving postoperative adjuvant chemotherapy with uracil and tegafur (UFT) or fluorouracil (5-FU) from the Taiwan National Health Insurance Research Database from 2000 to 2015. The outcomes of the current study were disease-free survival (DFS) and overall survival (OS). Hazard ratios (HRs) were calculated by multivariate Cox proportional hazard regression models. We compared our effectiveness results from the literature by meta-analysis, which provided the best evidence. Severe adverse events were compared in meta-analysis of reported clinical trials. In the nationwide cohort study, UFT (14,486 patients) showed DFS similar to postoperative adjuvant chemotherapy (adjusted HR 1.037; 95% confidence interval [CI] 0.954-1.126; P = .397) and OS (adjusted HR 0.964; 95% CI 0.891-1.041; P = .349) compared with the 5-FU (866 patients). Our meta-analysis confirmed the similarity of effectiveness and found the incidence of leucopaenia was statistically significantly reduced in UFT (risk ratio 0.12; 95% CI 0.02-0.67; I2 = 0%). Through our analysis, we have confirmed that UFT is a well-tolerated adjuvant therapy choice, and has similar treatment efficacy as 5-FU in terms of DFS and OS in patients with Stage II and III colon cancer.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

36 keywords...

hide…